ATRA Share Price Performance
Recent ATRA News & Updates
No updates
Atara Biotherapeutics, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.30
- Gross Margin
- 17.81%
- Net Profit Margin
- -7.83%
- Debt/Equity Ratio
- 0%
Atara Biotherapeutics, Inc. Competitors
About ATRA
- Founded
- 2012
- Employees
- 89
- CEO
- WebsiteView website
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
U.S. Market Performance
- 7 Days: -0.6%
- 3 Months: 11.8%
- 1 Year: 16.8%
- Year to Date: 7.5%
Over the last 7 days, the market has remained flat, although notably the Healthcare sector declined by 4.2%. Meanwhile, the market is actually up 17% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading